A therosclerotic coronary heart disease (CHD) is a multifactorial disease with a prominent inflammatory vascular component that remains the leading cause of death in most developed countries and will soon become the leading cause of death in developing countries. 1 Atherosclerosis involves an interaction between modified lipoproteins, monocyte-derived macrophages, T cells, and the normal cellular elements of the arterial wall, resulting in the formation of atherosclerotic plaques. Plaque rupture and thrombosis can result in myocardial infarction (MI) and stroke. 2 Despite rapid advances in the genetic and genomic analysis of CHD in recent years, the molecular elements and the mechanisms involved in CHD pathogenesis remain unclear. Understanding MI, with many representing novel risk loci. 3, 4 Identifying the casual genes and mechanisms underlying GWAS signals, however, remains a challenging task. In addition, even large-scale GWAS involving tens of thousands of cases and controls are unlikely to explain >15% to 20% of the heritability of CHD and MI. 5 Therefore, further experiments and integrative analyses are needed to elucidate functional mechanisms underlying CHD risk loci and to identify the missing heritability.
At the gene expression level, peripheral blood has been investigated widely because of its ease of collection and its pathological relevance to CHD, because multiple blood constituents seem to play a role in plaque accumulation, rupture, and thrombus formation. 6 Gene expression changes in whole blood of patients with CHD may reflect the interaction of genetic predisposition, disease activity, immunity, thrombosis, metabolism, and environmental modifiers underlying disease mechanisms. In recent studies, [7] [8] [9] mRNA profiling of tens to >100 CHD cases has yielded lists of differentially expressed genes in an effort to identify effective markers of disease severity. Most of these studies, however, identified relatively few significantly differentially expressed genes between cases and controls at a stringent statistical cutoff, and there was little overlap in the gene signatures of different CHD expression profiling studies. For instance, there is no common CHD gene signature among 160 genes reported by Sinnaeve et al, 7 50 genes reported by Wingrove et al, 8 and 23 genes identified by Rosenberg et al. 9 This failure to replicate may be attributable to the small sample sizes, differences in phenotypes or experimental platforms, and the low levels of differential expression of single genes.
To address the limitations of previous studies, we designed a systems biology framework to explore the molecular underpinnings of CHD via integration of whole blood gene expression profiles of RNA collected from Framingham Heart Study (FHS) participants with network approaches, GWAS, and genetics of gene expression ( Figure  1 ). The FHS case-control study includes 188 pairs of prevalent CHD cases and age-and sex-matched controls. In our companion article, we identified 35 differentially expressed genes between CHD cases and controls at false discovery rate<50%. 10 To extend on results of analysis of differential gene expression, in this investigation, we first constructed coexpression networks and compared the robust coexpression patterns of cases with controls to identify differential coexpression modules (differential modules [DMs] ) that demonstrate gene coregulation in cases but not in controls or vice versa. The CHD DMs were then integrated with singlenucleotide polymorphisms (SNPs) associated with altered gene expression (expression-associated SNPs [eSNPs] or eQTLs) from CHD-relevant tissues as well as CHD and CHD risk factor GWAS association results to look for enrichment of CHD risk eSNPs among the DM genes. This integration allowed us to differentiate causal (ie, upstream) from reactive (ie, downstream) DMs. Last, using a key driver (KD) analysis that leverages DMs and graphical networksincluding external tissue-specific Bayesian networks (BNs) and protein-protein interaction (PPI) networks-we identified putative regulators of the DMs and derived a CHD subnetwork.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Clinical Characteristics of the Study Sample
The case-control study included 188 CHD cases and 188 matched controls. Demographic data and the clinical and laboratory characteristics of the study participants are summarized in Table 1 . CHD cases had a higher prevalence of hypertension than controls (P=0.019).
Figure 1.
Systems biology analysis flow chart depicting the process of identifying coronary heart disease (CHD) causal modules and key drivers (KDs). The overall analysis includes 3 steps. First, coexpression networks are constructed from CHD cases and controls separately. CHD differential modules (DMs) are then identified by comparing the network structures between cases and controls. Step 2, the DMs are then integrated with genome-wide association studies (GWAS) of CHD and related traits using a single-nucleotide polymorphism set enrichment analysis to identify causal DMs. Third, key regulatory genes or KDs are identified for the causal DMs based on directional networks derived from independent studies using a KD analysis algorithm. PPI indicates protein-protein interaction.
Construction of Coexpression Networks for CHD and Identification of DMs
Using differential expression analysis, we identified 35 genes that were differentially expressed between CHD cases and controls at a false discovery rate <50%; these results are summarized in our companion report. 10 We hypothesized that alterations in the gene regulatory network architecture may better reflect the underlying molecular differences between groups. Therefore, we compared coexpression networks between CHD cases and controls to identify differential coexpression modules (DMs).
Using the previously developed Weighted Gene Coexpression Network Analysis method, 11 we constructed gene coexpression networks for CHD cases and their corresponding controls, separately. A total of 12 coexpression network modules were identified for CHD cases and 12 for controls ( Figure III in the online-only Data Supplement). We tested whether modules were conserved between case and control networks by examining the overlap in gene memberships using Fisher exact test. Modules that overlapped at P<2.0×10 −3 (corresponding to Bonferroni-corrected P<0.05) were defined as conserved between networks. If a module in one network did not have a corresponding conserved module in the other network, it was considered a DM. Two DMs-the CHD_tan module and the control_tan module containing 38 and 79 genes, respectively-differed between CHD cases and controls ( Figure IV and Table III in the online-only Data Supplement). The genes in these 2 CHD DMs did not show any overlap with the 35 differential expression signatures, 10 suggesting that the altered gene coexpression pattern and differential expression of individual genes captured different biological signals.
Functional Annotation of the DMs
To understand the biological pathways and functional categories of the DMs, we conducted functional enrichment analysis. As shown in Table 2 , the top enriched gene ontology biology process term in the control_tan module is B-cell activation, with 9 of 51 module genes (existing in the gene ontology database) overlapping with 103 genes in this pathway (19.8-fold enrichment, Bonferroni corrected enrichment P=5.6×10 −10 ). These B-cell-related genes demonstrated strong coexpression in controls, but not in CHD cases, indicating that B-cell dysregulation may be a major factor in atherosclerotic CHD. In contrast to the control_tan module, the CHD_tan module was identified in CHD cases but not in controls. The CHD_tan module is enriched for genes involved in ion transport (gene ontology category; Bonferroni-corrected enrichment P=0.025). These results suggest a reorganization and shift of immune response and ion transporter pathways, with the former disrupted and the later enhanced in CHD.
DMs Are Enriched for CHD Risk eSNPs
By virtue of the case-control design of this study, blood samples from the CHD cases used for gene expression profiling were drawn after the CHD events, thus some of the DMs we identified are potentially downstream of CHD rather than being causal. To identify causal DMs, we integrated the CHD DMs with CHD-related GWAS databases to look for enrichment of risk SNPs among DMs, with the rationale that genes harboring disease-risk SNPs are putatively causal for the disease of interest, 12, 13 because genotype does not change in response to disease occurrence.
We used SNP set enrichment analysis (SSEA; see description in the Methods section) to test whether the DMs for CHD are likely to play causal roles in disease development by evaluating the overall association P value distribution of putative functional SNPs among DM genes in comparison with the null distribution. All 5 control CHD gene sets from different resources (details in Materials and Methods) were highly enriched with low-P value CHD association eSNPs in the Coronary ARteryDIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) CHD GWAS 3 (Table IV in the online-only Data Supplement). These results confirm the sensitivity of SSEA to identify gene sets suspected of being causal of CHD.
The control-specific DM, control_tan, was not only enriched for risk eSNPs for CHD in the CARDIoGRAM CHD GWAS (1.6-fold enrichment; P=0.04 and 1.5×10 −5 from Kolmogorov-Smirnov [KS] and Fisher tests, respectively), but also is enriched for low-P value associations for lipid traits, including high-density lipoprotein cholesterol (KS P=4.8×10 −12 and Fisher P=7.8×10 −9 ), low-density lipoprotein cholesterol (KS P=9.0×10 −19 and Fisher P=1.9×10 −26 ), and total cholesterol (KS P=4.2×10 −21 and Fisher P=7.5×10 −28 ) in the Global Lipid Genetics Consortium lipid GWAS, 14 suggesting that this DM may play a role in CHD pathogenesis via effects on atherogenic lipids ( Table IV in the online-only Data Supplement  SSEA results for CHD-related gene sets, and Table V in the online-only Data Supplement CHD risk eSNPs for the con-trol_tan module). The CHD_tan DM, on the contrary, did not show enrichment for CHD risk SNPs (enrichment P=0.49 and 0.85 from Fisher and KS tests, respectively), and thus may be reactive rather than causal. The differential gene expression signatures identified at false discovery rate<50% also failed to show any enrichment for CHD risk SNPs.
Identification of Key Drivers of the CHD Causal DM and Their Associated Subnetworks via Network Models Derived From Orthogonal Studies
We speculated that the CHD causal DM we identified (con-trol_tan) was driven by key regulatory genes with broad impact on this network module when perturbed. Such key regulatory genes or KDs can serve as candidate genes for therapeutic intervention. To identify KDs, we projected the genes within the CHD causal DM onto the precompiled directional networks, including tissue-specific BNs ( Table II in the onlineonly Data Supplement) 15, 16 and nondirectional PPI networks 17 from previous studies. At a Bonferroni-corrected P<0.05, we identified 59 unique KDs for the CHD causal module in the 6 tissue-specific BNs (59 KDs for blood, 0 for liver, 1 for fat, 1 for kidney, 0 for heart, and 0 for muscle) and 1 PPI network (0 KD). The human blood BN gave rise to the largest number of KDs (n=59) in contrast to the limited number of KDs in other tissue-specific networks. This is not surprising given that the DMs were identified from human blood expression profiles, confirming the tightly coregulated relationships among the DM genes in blood rather than in other tissues. Furthermore, as the DMs were from the FSH and the blood BN used for KD identification was constructed from an independent Icelandic cohort, 15 the consistency between the 2 networks cross-validated our results. Among the 59 KDs, 27 KDs contained eSNPs showing association with CHD or its risk factors at P<0.05; 7 contained eSNPs at P<1.0×10 −3 , and 3 contained eSNPS at P<1.0×10 −4 in GWAS ( Table VI in We further prioritized the 59 KDs based on 4 elements: (1) consistency of the KD across multiple directional networks, that is, a higher priority is given to KDs driving the CHD causal DM in >1 tissue-specific/PPI network; (2) whether the KD is a DM gene itself; (3) whether the KD contains eSNPs showing evidence of association with CHD and its risk factors at P<1.0×10 −3 (the liberal GWAS P value cutoff was used here because the GWAS information was not considered alone but integrated with several levels of additional data to prioritize genes and reduce false discoveries); and (4) the P value of the KD based on the KD analysis algorithm ( Table VI in (Table 3) , TNFRSF13C and SPIB appeared in 2 networks-TNFRSF13C in adipose and blood and SPIB in kidney and blood-and were considered as multitissue KDs; the remaining were blood-specific KDs. In fact, Sage et al 18, 19 reported that in Ldlr knockout mice, deletion of the B-cell activating factor receptor (BAFFR, encoded by the multitissue KD TNFRSF13C) reduced aortic root atherosclerosis significantly. In addition, Fretz et al 20 observed that knockout of another top KD, EBF1, in mice induced defects in lipid metabolism, adipose tissue deposition, and impaired glucose mobilization. 20 Therefore, some of the top KDs we identified are supported by existing experimental evidence for their relevance to metabolism, atherosclerosis, or other CHD-related phenotypes.
As shown in Figure 2 , these top KDs constitute a tightly linked subnetwork with certain elements being tissuespecific and others showing cross-tissue connections. The KDs are at the center of the subnetwork and hence represent master regulators of this subnetwork. Not surprisingly, this subnetwork, which includes 152 genes depicted in Figure  2 , is significantly enriched for immune response (gene ontology functional category) and B-cell receptor signaling pathways (Bonferroni-corrected P=1.9×10 −6 and P=5.1×10 −6 , respectively). In addition, the subnetwork is highly enriched for genes whose eSNPs show low-P value associations for both CHD in the CARDIoGRAM GWAS (enrichment P=9.2×10 −3 and 3.8×10 −3 from Fisher and KS tests, respectively) and CHD risk traits, including systolic blood pressure and diastolic blood pressure in the International Consortium of Blood Pressure GWAS, and lipid traits (high-density lipoprotein, low-density lipoprotein, and total cholesterol) in the Global Lipid Genetics Consortium GWAS (Table IV in the online-only Data Supplement). Furthermore, 15 genes were candidate cardiovascular genes curated in the Genetic Association Database (http://geneticassociationdb.nih.gov/).
All these lines of evidence support the relevance of the KDs and their related subnetwork to atherosclerotic CHD.
Discussion
We conducted a systems biology investigation of gene expression in a case-control study of CHD using network approaches. To our knowledge, this is the largest gene expression study to date of CHD incorporating multidimensional genome-wide data from multiple sources, including GWAS, gene expression, eSNPs, and molecular networks.
Extending a traditional approach that targeted differentially expressed individual genes, 10 we compared the coexpression network structure in CHD cases with that in matched controls to derive differential network modules. The advantage of a network approach is that it provides a contextual framework to explain how genes interact with each other differently in CHD cases versus controls. Previous research has reported strong correlations of gene coexpression patterns with causal disease mechanisms. For example, a conserved coexpression module was discovered in liver and adipose tissues in mouse and human, were found to be correlated with multiple metabolic traits, 15, 23 and its causal relationship with metabolic diseases was further validated experimentally. [23] [24] [25] Using coexpression network analyses, we identified 2 DMs that demonstrated differential coexpression patterns between cases and controls. The 79 genes in the control_tan module ( Table III in the online-only Data Supplement) showed a tightly coregulated pattern in controls, but a disrupted The key drivers (KDs) were ranked based on 4 elements: (1) consistency of the KD across multiple directional networks; (2) whether the KD is a DM gene itself; (3) whether the KD contains eSNPs showing evidence of association with CHD and its risk factors at P<1.0×10 −3 ; and (4) the P value of the KD based on the Key driver analysis algorithm. BAFF indicates B-cell activating factor; BMI, body mass index; CABG, coronary artery bypass grafting; CARDIoGRAM, Coronary ARteryDIsease Genome wide Replication and Meta-analysis; CHD, coronary heart disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; DIAGRAM, DIAbetes Genetics Replication and Meta-analysis; eSNP, expression-associated single-nucleotide polymorphism; FHS, Framingham Heart Study; GIANT, Genetic Investigation of Anthropometric Traits; GLGC, Global Lipid Genetics Consortium; GO, gene ontology; GWAS, genome-wide association studies; HDL, high-density lipoprotein; ICBP, International Consortium of Blood Pressure; MI, myocardial infarction; PPI, protein-protein interaction; PTCA, percutaneous transluminal coronary angioplasty with or without a stent; SBP, systolic blood pressure; SSEA, SNP set enrichment analysis; TC, total cholesterol; TG, triglycerides; and WGCNA, Weighted Gene Coexpression Network Analysis. coexpression pattern in CHD cases. B-cell-centered immune genes were highly enriched in this module, along with a suggestive enrichment for lipid transport genes (ABCA6, ABCA9, ABCB4, APOD, and OSBPL10). This is consistent with the known roles of immune response and lipid-related pathways in atherogenesis. At a cellular level, atherosclerosis involves lipid accumulation in the artery wall, which can lead to plaque rupture, platelet aggregation, and coagulation, leading to occlusive thrombus and MI. Immune responses are involved in multiple phases of atherogenesis. 6, 26 From the inception of atherogenesis, multiple immunocytes, including macrophages, T cells, and mast cells, are recruited by adhesion molecules or leukocyte receptors expressed on the surface of endothelial cells. The precise role of B cells in atherosclerosis, however, is relatively less well studied. In the traditional view, B cells are thought to play a protective role against atherosclerosis. 27 Kyaw et al 28 found that innate-like B1 cells mediate protection from atherosclerosis via the secretion of natural IgM antibodies. The tightly coregulated pattern of B-cell-related genes in controls and the disrupted pattern in CHD cases found in our study are consistent with an atheroprotective role of B cells. A recent study, however, showed reduced atherosclerosis in mice after B-cell depletion, 29 suggesting that B-cell subpopulations may have contrasting roles in the pathogenesis of atherosclerosis. 30 It is of note that the blood samples used in this study were collected after the onset of clinical CHD events. Therefore, the differential gene signatures and DMs identified here could be a consequence of CHD or its treatment (ie, downstream signals) rather being causal of CHD (ie, upstream signals). GWAS has identified scores of loci associated with CHD and CHD risk factors, with ≈27 loci for CHD or MI, 3,4 30 for blood pressure, 31-33 95 for lipids, 14 28 for body mass index, 34 and 27 for type 2 diabetes mellitus. 35 Traditional GWAS, however, can only detect common loci yielding stringent P value associations, typically P<5×10 -8 , and susceptibility loci with more subtle effects are missed. In an attempt to separate the causal and reactive effects of the DMs that differed between CHD cases and controls, we used SSEA to integrate our gene expression findings with publicly available GWAS results for CHD and its risk factors based on the reasoning that genetic variation is unaltered over time and that converging genetic associations with CHD gene expression signatures will highlight causal genes and pathways. SSEA is a complementary approach to single-point analysis, because it tests the overall association of a set of SNPs derived from a given gene set to a trait rather than a single SNP or gene association with a trait, 12 thus empowering the identification of biological pathways, functional categories, or networks. While individual genes may only exert subtle effects on a trait, collectively they may contribute to disease susceptibility on a larger scale. Another advantage of SSEA lies in the fact that it uses eSNPs (SNPs associated with the expression levels of genes) from disease-relevant tissues to map genes to their functional SNPs. This is in contrast to distance-based gene-to-SNP mapping used in other studies. [36] [37] [38] The control_tan DM (enriched for genes involved in B-cell activation/differentiation and immune function), but not the CHD_tan DM (enriched for ion transport genes), was identified as a causal module showing enrichment for eSNPs with low-P value associations from CHD GWAS in CARDIoGRAM 3 and lipid traits GWAS in Global Lipid Genetics Consortium. 14 These results indicate that B-cell-related immune function may exert a causal effect on CHD and on lipids. As discussed above, previous studies support a causal role of B cells in atherogenesis. In addition, recent research by Fretz et al 20 Figure 2 . Top key drivers (KDs) of the coronary heart disease (CHD) causal module and the associated subnetwork. The subnetwork was derived from the top 20 KDs using the tissue-specific networks from which the KDs were identified. The nodes of the largest size in the network are the top 20 KDs, and the middle-sized nodes represent other KDs and genes in the CHD causal model. Red rectangular, red circular, and green circular nodes are multitissue KDs, blood-specific KDs, and causal differential module (DM) genes, respectively. The network graph was drawn by ProteoLens. 22 revealed direct evidence that B-cell dysfunction (Ebf1 −/− mice) results in lipid abnormalities. Therefore, our results not only support previous phenotypic observations linking B cells to both atherogenesis and lipid dysregulation, but also provide network and genetic support at the molecular level.
We further identified and prioritized putative key regulatory genes or KDs for the CHD causal DM based on the global networks derived from tissue-specific BNs and PPI networks. We identified 59 KDs for the control_tan module, 2 from multiple tissue networks and 57 from the blood-specific network. After prioritization of the 59 KDs, we retrieved a subnetwork derived from the top KD and found that the KDs and other control_tan DM genes form a tightly linked subnetwork. Perturbations of the multitissue KD, TNFRSF13C, and a tissue-specific KD, EBF1, in animal models have been shown to affect aortic root atherosclerosis and other CHD-related phenotypes. 18, 20 Therefore, the subnetwork structure and the KDs we uncovered provide both known CHD candidate genes with experimental support and novel candidate genes that warrant further validation.
In summary, we systematically compared the gene expression features of 188 CHD cases and 188 matched controls from the FHS via network modeling. Orthogonal studies incorporating CHD and CHD risk factor GWAS and datadriven gene regulatory networks from human and mouse models were integrated in this analysis to infer casual effects and possible pathological molecular mechanism. We found B-cell-centered immune function to be related to CHD pathogenesis. We hypothesize that disruption of gene coregulation of a B-cell-related DM via KDs contributes to CHD susceptibility. Our results provide further evidence supporting a critical role of adaptive immunity in atherosclerosis, especially aspects involving B-cell function. Consequently, we speculate that immunomodulatory therapy may be useful to prevent or treat atherosclerotic CHD. 39 
